genOway Société anonyme (EPA:ALGEN)

Market Cap	22.50M -21.5%
Revenue (ttm)	28.60M +3.9%
Net Income	927.75K -49.3%
EPS	n/a
Shares Out	9.22M
PE Ratio	24.25
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,371
Open	2.400
Previous Close	2.440
Day's Range	2.400 - 2.410
52-Week Range	2.100 - 3.200
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 18, 2026

About genOway Société anonyme

genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 157
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALGEN

Financial Performance

In 2025, genOway Société anonyme's revenue was 28.60 million, an increase of 3.88% compared to the previous year's 27.53 million. Earnings were 927,754, a decrease of -49.32%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 3, 2026

Data Sources Report a data error